The Effect of Hawthorn on Lipoprotein Cholesterol Ratio in Schizophrenics With Antipsychotics
NCT ID: NCT03663465
Last Updated: 2018-09-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
135 participants
INTERVENTIONAL
2013-01-01
2014-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objective: Therefore, this study aimed to investigate the effect of Hawthorn on lipid profile levels in schizophrenic patients treated with antipsychotics.
Design, Setting, and Participants: A longitudinal case-control study was used in a general hospital in Taiwan. A total of 59 schizophrenics treated with antipsychotics, and 76 healthy adult subjects, who were all hospital workers, were enrolled in this study.
Main outcomes and measures: All participants received Hawthorn at a dose of 3 gm/day for six months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Antiatherogenic Properties of HDL in Psychiatric Patients With and Without Antipsychotic Therapy
NCT01215383
Experience of Horticultural Group Therapy Among People With Chronic Schizophrenia
NCT05948696
Therapeutic Effect of Cassia Seed in Obesity of Patients With Schizophrenia
NCT04252131
The Study of Atypical Antipsychotics-induced Metabolic Disturbances
NCT00937755
Open-label Study of Curcumin C-3 Complex in Schizophrenia
NCT01875822
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hawthorn and SGAs
SGAs has a dose of 3-20 gm/day, Hawthorn at a dose of 3 gm/day for six months.
Hawthorn
Hawthorn tablet
SGAs
SGAs tablet
Hawthorn
Hawthorn at a dose of 3 gm/day for six months.
Hawthorn
Hawthorn tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hawthorn
Hawthorn tablet
SGAs
SGAs tablet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All participants in the case group had previously received antipsychotic treatment for a period of time.
Exclusion Criteria
* Participants were pregnant and lactating women in both group, were excluded.
16 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Calo Psychiatric Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
For-Wey Lung
Superintendent and Attending physician
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MAB101-109
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.